Surveillance, CDKN2A and survival of familial melanoma.
作者信息
van Doorn Remco
机构信息
Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
出版信息
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):218-219. doi: 10.1111/jdv.18796.
Abstract
摘要
相似文献
1
Surveillance, CDKN2A and survival of familial melanoma.家族性黑色素瘤的监测、CDKN2A与生存情况
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):218-219. doi: 10.1111/jdv.18796.
2
The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations.CDKN2A基因的A148T变体与法国和意大利人群的黑色素瘤风险无关。
J Invest Dermatol. 2006 Jul;126(7):1657-60. doi: 10.1038/sj.jid.5700293. Epub 2006 Apr 13.
3
Familial features affecting the melanoma risk in -negative melanoma families: a study based on the Swedish Cancer Registry.影响黑色素瘤阴性家族中黑色素瘤风险的家族特征：一项基于瑞典癌症登记处的研究。
Acta Oncol. 2023 Dec;62(12):1967-1972. doi: 10.1080/0284186X.2023.2265052. Epub 2023 Nov 25.
4
Absence of germline epimutation of the CDKN2A gene in familial melanoma.家族性黑色素瘤中CDKN2A基因种系表观突变的缺失。
J Invest Dermatol. 2009 Mar;129(3):781-4. doi: 10.1038/jid.2008.287. Epub 2008 Sep 25.
5
Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study.CDKN2A 种系突变与黑色素瘤患者生存率之间无关联：一项回顾性队列研究。
J Am Acad Dermatol. 2022 Aug;87(2):479-482. doi: 10.1016/j.jaad.2021.10.024. Epub 2021 Oct 23.
6
CDKN2A testing threshold in a high-risk Australian melanoma cohort: number of primaries, family history and young age of onset impact risk.澳大利亚高危黑色素瘤队列中的CDKN2A检测阈值：原发肿瘤数量、家族史和发病年龄较轻对风险的影响
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e797-e798. doi: 10.1111/jdv.16627. Epub 2020 Jul 9.
7
genetic testing in melanoma-prone families in Sweden in the years 2015-2020: implications for novel national recommendations.2015-2020 年瑞典黑色素瘤易感家族的基因检测：对新的国家建议的影响。
Acta Oncol. 2021 Jul;60(7):888-896. doi: 10.1080/0284186X.2021.1914346. Epub 2021 May 4.
8
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.患有多发性皮肤黑色素瘤个体中的CDKN2A种系突变。
Cancer Res. 2000 Dec 15;60(24):6864-7.
9
Pediatric melanoma in melanoma-prone families.黑色素瘤易患家族中的小儿黑色素瘤。
Cancer. 2018 Sep 15;124(18):3715-3723. doi: 10.1002/cncr.31641. Epub 2018 Sep 12.
10
Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma.巴西遗传性皮肤黑色素瘤患者的种系CDKN2A突变
Fam Cancer. 2014 Dec;13(4):645-9. doi: 10.1007/s10689-014-9736-1.
引用本文的文献
1
Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant.携带种系CDKN2A致病变异的家庭中的心理困扰与生活质量
Mol Genet Genomic Med. 2025 Feb;13(2):e70045. doi: 10.1002/mgg3.70045.
2
High frequency of melanoma in /./.中黑色素瘤的高发生率
Theranostics. 2024 Nov 4;14(19):7470-7487. doi: 10.7150/thno.97475. eCollection 2024.
3
Sun protection behaviors, healthcare access, and smoking among melanoma survivors.黑色素瘤幸存者的防晒行为、医疗保健获取情况及吸烟情况。
J Cancer Surviv. 2024 Dec 9. doi: 10.1007/s11764-024-01727-8.
4
Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.手术在转移性黑色素瘤中的作用及黑色素瘤分子特征综述。
Cells. 2024 Mar 7;13(6):465. doi: 10.3390/cells13060465.
本文引用的文献
1
Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.CDKN2A 基因突变携带者和非携带者纳入家族性黑色素瘤皮肤监测计划前后的黑色素瘤特异性生存。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):284-292. doi: 10.1111/jdv.18589. Epub 2022 Oct 1.
2
Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study.CDKN2A 种系突变与黑色素瘤患者生存率之间无关联：一项回顾性队列研究。
J Am Acad Dermatol. 2022 Aug;87(2):479-482. doi: 10.1016/j.jaad.2021.10.024. Epub 2021 Oct 23.
3
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.CDKN2A 种系突变与意大利黑色素瘤患者队列的不良生存无关。
J Am Acad Dermatol. 2019 May;80(5):1263-1271. doi: 10.1016/j.jaad.2018.07.060. Epub 2018 Sep 28.
4
Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.CDKN2A 双等位基因缺失通过 BRN2 激活引发黑色素瘤侵袭。
Cancer Cell. 2018 Jul 9;34(1):56-68.e9. doi: 10.1016/j.ccell.2018.05.014.
5
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.胚系 CDKN2A 突变状态与家族性黑色素瘤病例的生存关系。
J Natl Cancer Inst. 2016 Jun 10;108(11). doi: 10.1093/jnci/djw135. Print 2016 Nov.
6
Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families.CDKN2A 突变型黑色素瘤家族监测的有效性及失败原因。
J Am Acad Dermatol. 2011 Aug;65(2):289-296. doi: 10.1016/j.jaad.2010.06.067. Epub 2011 May 12.
7
Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.携带细胞周期蛋白依赖性激酶抑制剂2A（CDKN2A）始祖突变（p16-莱顿突变）的阳性黑色素瘤家族中，除黑色素瘤外其他癌症的发病风险增加。
Clin Cancer Res. 2008 Nov 1;14(21):7151-7. doi: 10.1158/1078-0432.CCR-08-0403.
8
Management of familial melanoma.家族性黑色素瘤的管理
Lancet Oncol. 2007 Jan;8(1):46-54. doi: 10.1016/S1470-2045(06)71010-5.
Zotero 插件